The DOI matches its Crossref record.
Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis
Open accessAbstract
We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin accumulate in tumors and are metabolized by malignant cells. MTX, covalently coupled to human serum albumin (MTX-HSA) for cancer treatment, is currently being evaluated in phase II clinical trials. Because synovium of patients with rheumatoid arthritis (RA) shares various features observed also in tumors, albumin-based drug targeting of inflamed joints might be an attractive therapeutic approach. Therefore, the pharmacokinetics of albumin and MTX in a mouse model of arthritis was examined. Additionally, uptake of albumin by synovial fibroblasts of RA patients and the efficacy of MTX and MTX-HSA in arthritic mice were studied. The results show that when compared with MTX, significantly higher amounts of albumin accumulate in inflamed paws, and significantly lower amounts of albumin are found in the liver and the kidneys. The protein is metabolized by human synovial fibroblasts in vitro and in vivo. MTX-HSA was significantly more effective in suppression of the onset of arthritis in mice than was MTX. In conclusion, albumin appears to be a suitable drug carrier in RA, most likely due to effects on synovial fibroblasts, which might increase therapeutic efficacy and reduce side effects of MTX.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Biopolymer based nanomaterials in drug delivery systems: A review
Jacob, J., Haponiuk, J. T., Thomas, S., & Gopi, S. (2018) · Materials Today Chemistry · doi:10.1016/j.mtchem.2018.05.002 · Cited by 573
Lin, T., Zhao, P., Jiang, Y., Tang, Y., Jin, H., Pan, Z., He, H., Yang, V. C., & Huang, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b04268 · Cited by 527
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Metadata
- Authors
- Wunder, A., Müller-Ladner, U., Stelzer, E. H. K., Funk, J., Neumann, E., Stehle, G., Pap, T., Sinn, H., Gay, S., & Fiehn, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05-01
- Volume
- 170
- Issue
- 9
- Pages
- 4793-4801
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1605132184
- Cited by
- 220
- References
- 0
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis. https://app.cochat.ai/papers/10.4049/jimmunol.170.9.4793
- The paper
- Wunder, A., Müller-Ladner, U., Stelzer, E. H. K., Funk, J., Neumann, E., Stehle, G., Pap, T., Sinn, H., Gay, S., & Fiehn, C. (2003). Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis. The Journal of Immunology. https://doi.org/10.4049/jimmunol.170.9.4793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.